Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Rhea-AI Summary

Oruka Therapeutics (Nasdaq: ORKA) announced participation and presentations at multiple investor conferences in February–March 2026, including Guggenheim Emerging Outlook, TD Cowen, UBS Biotech Summit Miami, Jefferies Biotech on the Beach, Leerink Global Healthcare, and Barclays Global Healthcare.

Presentation dates and times are listed; a webcast and replay will be available on the Oruka investor events website.

News Market Reaction – ORKA

+0.64%

1 alert

+0.64% News Effect

On the day this news was published, ORKA gained 0.64%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ORKA-002 half-life: 75–80 days Phase 1 sample size: 24 patients Planned Phase 2 size: ~160 patients +5 more

8 metrics

ORKA-002 half-life 75–80 days Phase 1 interim data reported Jan 12, 2026

Phase 1 sample size 24 patients ORKA-002 Phase 1 trial

Planned Phase 2 size ~160 patients Planned ORCA-SURGE Phase 2 psoriasis trial in 1H 2026

Cash & securities $500.9M As of Sept 30, 2025 (Q3 2025 results)

Resale registered shares 39,425,806 shares Amended resale registration statement (S-3/A) filed Oct 14, 2025

Shares outstanding 48,384,150 shares As of Sept 19, 2025 in resale filing

Resale as % of outstanding 59% Resale Shares vs outstanding, assuming warrant exercises and conversions

Vanguard ownership 2,453,530 shares (5.06%) Schedule 13G as of Dec 31, 2025

Market Reality Check

Price: $35.56 Vol: Volume 499,312 is near th...

normal vol

$35.56 Last Close

Volume Volume 499,312 is near the 20-day average of 490,990 (relativity 1.02x). normal

Technical Price 33.05 is trading above the 200-day MA at 20.26, indicating a strong pre-news uptrend.

Peers on Argus

ORKA gained 5.19% while key biotech peers showed mixed moves (e.g., PVLA +4.14%,...

ORKA gained 5.19% while key biotech peers showed mixed moves (e.g., PVLA +4.14%, RZLT +5.76%, SVRA and BCAX down). No peers appeared in the momentum scanner, pointing to a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Clinical data update	Positive	+10.2%	Positive interim Phase 1 data for ORKA-002 and trial plans for ORKA-001.
Jan 06	Conference participation	Neutral	-1.0%	Announcement of presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Dec 11	Board/management change	Positive	-0.1%	New board member with significant commercial experience and related board transition.
Nov 12	Earnings and update	Positive	+0.3%	Q3 2025 results with strong cash position and progression of ORKA-001/002 programs.
Oct 29	Conference participation	Neutral	+0.6%	Multiple November investor conference presentations on chronic skin disease biologics.

Pattern Detected

Recent news has mostly seen modest, aligned price reactions, with strong upside on positive clinical data and a slight divergence on a management change.

Recent Company History

Over the last few months, Oruka has combined clinical progress and corporate activity. On Nov 12, 2025, Q3 results highlighted cash of $500.9M and advancement of ORKA-001/002, with a small positive move. Multiple conference announcements on Oct 29, 2025 and Jan 6, 2026 produced muted reactions. Positive interim Phase 1 data on Jan 12, 2026 drove a 10.16% gain, underscoring sensitivity to clinical catalysts. A December 2025 board transition saw a slight negative reaction.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-14

An amended resale registration statement covers up to 39,425,806 common shares from prior financings, including private placement shares, pre-funded warrants, and Series B Preferred conversions. The company is not selling shares in this registration and will not receive sale proceeds, aside from nominal warrant exercise cash. The registered Resale Shares represent about 59% of outstanding shares as of Sept 19, 2025, highlighting potential secondary-market supply from existing holders.

Market Pulse Summary

This announcement highlights Oruka’s engagement in multiple upcoming biotech and healthcare conferen...

Analysis

This announcement highlights Oruka’s engagement in multiple upcoming biotech and healthcare conferences, which may increase visibility for its chronic skin disease biologics portfolio. Recent history shows more pronounced share moves around clinical data, such as the positive Phase 1 results on Jan 12, 2026, while prior conference news had modest impact. Investors may watch for future clinical updates, capital markets activity under the existing S-3/A, and how the company deploys its $500.9M cash position.

Key Terms

biologics, plaque psoriasis

2 terms

biologics medical

"a clinical-stage biotechnology company developing novel biologics designed to set a new"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

plaque psoriasis medical

"treatment of chronic skin diseases including plaque psoriasis, today announced its"

A chronic autoimmune skin condition that causes raised, red, scaly patches where the skin sheds too quickly, like a tree producing bark in clumps instead of renewing smoothly. It matters to investors because prevalence, severity, and treatment options drive demand for therapies, shape clinical trial design and regulatory review, and affect potential market size, pricing and reimbursement for drugs or devices aimed at relieving symptoms or altering the underlying immune response.

AI-generated analysis. Not financial advice.

MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026
Date: Thursday, February 12^th, 2026
Presentation Time: 10:30AM ET

TD Cowen 46^th Annual Health Care Conference
Date: Tuesday, March 3^rd, 2026
Presentation Time: 1:10PM ET

UBS Biotech Summit Miami
Date: Monday March 9^th, 2026

Jefferies Biotech on the Beach Summit
Date: March 10^th, 2026

Leerink Global Healthcare Conference
Date: March 11^th, 2026
Presentation Time: 1:00PM ET

Barclays 28^th Annual Global Healthcare Conference
Date: March 12^th, 2026
Presentation Time: 10:30AM ET

A webcast and replay of Oruka’s presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.

About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: 
Alan Lada 
(650)-606-7911 
alan.lada@orukatx.com 

FAQ

When is Oruka (ORKA) presenting at the Guggenheim Emerging Outlook: Biotech Summit?

Oruka will present at Guggenheim on February 12, 2026 at 10:30AM ET. According to Oruka, the presentation is part of a series of investor events and a webcast plus replay will be available on the company's investor events website for later viewing.

What are the dates and times for Oruka's (ORKA) TD Cowen and Barclays presentations?

Oruka is scheduled at TD Cowen on March 3, 2026 at 1:10PM ET and Barclays on March 12, 2026 at 10:30AM ET. According to Oruka, both presentations will be webcast with replays accessible on the investor events site.

Will Oruka (ORKA) webcast its presentations from the March 2026 conference roadshow?

Yes, Oruka will webcast its conference presentations and provide replays online. According to Oruka, investors can access live webcasts and archived replays via the company's investor events and presentations webpage.

Which Miami conference will Oruka (ORKA) attend in March 2026 and when?

Oruka will attend the UBS Biotech Summit Miami on March 9, 2026 and Jefferies Biotech on the Beach on March 10, 2026. According to Oruka, dates reflect its planned investor engagement schedule with webcasts available when provided.

Where can investors find Oruka's (ORKA) presentation replays and event details?

Investors can find presentation replays and event details on Oruka's investor events website. According to Oruka, the company will post live webcasts and archived replay links on its investor relations events and presentations page.

What is the purpose of Oruka's (ORKA) multiple conference presentations in Feb–Mar 2026?

The presentations are intended to update investors on Oruka's clinical-stage programs and corporate progress. According to Oruka, these meetings provide opportunities for investor Q&A and broader visibility via live webcasts and replay availability.